Conor Ramps Up Production Of CoStar Stent To Prep For U.S. Launch
This article was originally published in The Gray Sheet
Executive Summary
Conor Medsystems is already boosting manufacturing capacity in preparation for the U.S. launch of its CoStar drug-eluting stent, though the product is not slated to hit the market until late next year at the earliest
You may also be interested in...
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
Abbott Vascular Prospects Aid 23% Stock Gain In 2006 – Index Up 5.7%
Abbott's and Johnson & Johnson's guidance to the device industry in 2006 was that diversification is key and some acquisitions are too good to pass up
J&J Gains Next-Gen CoStar Stent Through $1.4 Bil. Conor Purchase
Johnson & Johnson hopes that its $1.4 bil. purchase of next-generation drug-eluting stent developer Conor Medsystems will help it retain top-tier market share as a flurry of new competitors joins the market